首页> 中文期刊> 《临床医药实践》 >玻璃酸钠联合复方倍他米松关节腔内注射治疗早期膝关节骨性关节炎的短期临床疗效观察

玻璃酸钠联合复方倍他米松关节腔内注射治疗早期膝关节骨性关节炎的短期临床疗效观察

         

摘要

Objective:To study the short-term clinical curative effect on sodium hyaluronate combined with compound recipe diprospan intraarticular injection for early knee osteoarthritis. Methods:All 175 early knee osteoarthritis patients were randomly divided into two groups:the research group treated with sodium hyaluronate combined with diprospan and the control group treated with sodium hyaluronate. The short-term clinical curative effect of the two groups were comparatively analyzed. Results:After treatment,the function of pain and knee were improved. Lysholm knee functional score in research group was higher than control group( P < 0 . 0 1 ). VAS pain score of the research group was lower compared with the control group( P <0. 01). Conclusion:Sodium hyaluronate combined with diprospan has good clinical curative effect of short-term on early knee osteoarthritis.%目的:研究玻璃酸钠联合复方倍他米松关节腔内注射治疗早期膝关节骨性关节炎的短期临床疗效。方法:选择膝关节骨性关节炎患者175例,根据治疗方法不同随机分为对照组(玻璃酸钠组)和实验组(玻璃酸钠联合复方倍他米松组),对比两者的临床疗效。结果:与治疗前相比,治疗后两组在疼痛和膝关节功能方面均得到了明显改善(P<0.01),且治疗后实验组的Lysholm评分高于对照组(P<0.01),视觉模拟评分法(VAS)评分低于对照组(P<0.01)。结论:玻璃酸钠联合复方倍他米松关节腔内注射对治疗早期膝关节骨性关节炎具有良好的协同作用,临床效果较好。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号